SCOTT ERICWOODMANSCOTT ERIC WOODMAN9414WOODMAN, SCOTT ERICAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1696081Authorship 1880282Authorship 1915976Authorship 19242116Authorship 1961261411888297Woodman SE, Schlegel A, Cohen AW, Lisanti MPBiochemistryMutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry. 2002 Mar 19; 41(11):3790-5.Biochemistry2002-03-19T00:00:002002Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1.22267918Patel SP, Woodman SEDrug design, development and therapyProfile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther. 2011; 5:489-95.Drug Des Devel Ther2011-12-16T00:00:002011Profile of ipilimumab and its role in the treatment of metastatic melanoma.23204132Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Liz?e G, Hwu PClinical cancer research : an official journal of the American Association for Cancer ResearchBRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.Clin Cancer Res2012-11-30T00:00:002012BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.23633454Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, S?sskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf DClinical cancer research : an official journal of the American Association for Cancer ResearchConjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013 Jun 15; 19(12):3143-52.Clin Cancer Res2013-04-30T00:00:002013Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.LeukemiaMelanoma Medical OncologySurgical OncologyMD AndersonJEFFREY EGERSHENWALDJEFFREY E GERSHENWALD8667GERSHENWALD, JEFFREY EProfessorJENNIFERWARGOJENNIFER WARGO9904WARGO, JENNIFERAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessor3.462950.00503416415research areas2.871440.0227556130coauthor of76.766614.813160similar to11107selected publicationsALEXANDERLAZARALEXANDER LAZAR9206LAZAR, ALEXANDERProfessorMICHAEL ADAVIESMICHAEL A DAVIES8753DAVIES, MICHAEL AAssociate ProfessorVICTORPRIETOVICTOR PRIETO8828PRIETO, VICTORProfessorCHANDRANICHATTOPADHYAYCHANDRANI CHATTOPADHYAY8925CHATTOPADHYAY, CHANDRANIAssistant ProfessorPATRICKHWUPATRICK HWU9108HWU, PATRICKProfessorAuthorship 2209066Authorship 2270681Authorship 2288841Authorship 2292833Authorship 2317258Authorship 2330691Authorship 233146814507673Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MPThe American journal of pathologyProteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol. 2003 Oct; 163(4):1663-75.Am J Pathol2003-10-01T00:00:002003Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins.19671763Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MAMolecular cancer therapeuticsActivity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009 Aug; 8(8):2079-85.Mol Cancer Ther2009-08-11T00:00:002009Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.20959481Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MACancer researchBasal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010 Nov 01; 70(21):8736-47.Cancer Res2010-10-19T00:00:002010Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.21084639Woodman SE, Mills GBProceedings of the National Academy of Sciences of the United States of AmericaAre oncogenes sufficient to cause human cancer? Proc Natl Acad Sci U S A. 2010 Nov 30; 107(48):20599-600.Proc Natl Acad Sci U S A2010-11-17T00:00:002010Are oncogenes sufficient to cause human cancer?22453016Woodman SECancer journal (Sudbury, Mass.)Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012 Mar-Apr; 18(2):148-52.Cancer J2012-03-01T00:00:002012Metastatic uveal melanoma: biology and emerging treatments.22733540Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SEClinical cancer research : an official journal of the American Association for Cancer ResearchCombination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15; 18(16):4345-55.Clin Cancer Res2012-06-25T00:00:002012Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.22809251Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KBJournal of cutaneous pathologyBRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012 Sep; 39(9):821-5.J Cutan Pathol2012-07-19T00:00:002012BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.Authorship 2445032Authorship 2447911Authorship 2449883Authorship 2452802Authorship 2453552Authorship 2457754Authorship 2466671Authorship 2542228Authorship 2552131Authorship 2573311Authorship 261418312138167Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MPThe Journal of biological chemistryCaveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 2002 Oct 11; 277(41):38988-97.J Biol Chem2002-07-23T00:00:002002Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade.12167625Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MPThe Journal of biological chemistryMicrovascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem. 2002 Oct 18; 277(42):40091-8.J Biol Chem2002-08-07T00:00:002002Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice.12223531Razani B, Woodman SE, Lisanti MPPharmacological reviewsCaveolae: from cell biology to animal physiology. Pharmacol Rev. 2002 Sep; 54(3):431-67.Pharmacol Rev2002-09-01T00:00:002002Caveolae: from cell biology to animal physiology.12689915Frank PG, Woodman SE, Park DS, Lisanti MPArteriosclerosis, thrombosis, and vascular biologyCaveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol. 2003 Jul 01; 23(7):1161-8.Arterioscler Thromb Vasc Biol2003-04-10T00:00:002003Caveolin, caveolae, and endothelial cell function.12839838Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MPAmerican journal of physiology. Cell physiologyPhenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. Am J Physiol Cell Physiol. 2003 Nov; 285(5):C1150-60.Am J Physiol Cell Physiol2003-07-02T00:00:002003Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.14633633Sotgia F, Bonuccelli G, Minetti C, Woodman SE, Capozza F, Kemp RG, Scherer PE, Lisanti MPThe American journal of pathologyPhosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. Am J Pathol. 2003 Dec; 163(6):2619-34.Am J Pathol2003-12-01T00:00:002003Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases.14713860Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, Lisanti MPThe Journal of urologyUrogenital alterations in aged male caveolin-1 knockout mice. J Urol. 2004 Feb; 171(2 Pt 1):950-7.J Urol2004-02-01T00:00:002004Urogenital alterations in aged male caveolin-1 knockout mice.19718013Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan DModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncCorrelation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009 Nov; 22(11):1446-56.Mod Pathol2009-08-28T00:00:002009Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.20457136Woodman SE, Davies MABiochemical pharmacologyTargeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010 Sep 01; 80(5):568-74.Biochem Pharmacol2010-05-08T00:00:002010Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.22140212Woodman SEClinical cancer research : an official journal of the American Association for Cancer ResearchBAP1tism of a tumor suppressor. Clin Cancer Res. 2012 Jan 15; 18(2):323-5.Clin Cancer Res2011-12-02T00:00:002011BAP1tism of a tumor suppressor.24551032Chattopadhyay C, Grimm EA, Woodman SEPloS oneSimultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014; 9(2):e83957.PLoS One2014-02-13T00:00:002014Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.Authorship 2648331Authorship 2660614Authorship 268074212759260Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, Lisanti MPThe American journal of pathologyCaveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol. 2003 Jun; 162(6):2059-68.Am J Pathol2003-06-01T00:00:002003Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli.15733789De Souza AP, Cohen AW, Park DS, Woodman SE, Tang B, Gutstein DE, Factor SM, Tanowitz HB, Lisanti MP, Jelicks LAMagnetic resonance imagingMR imaging of caveolin gene-specific alterations in right ventricular wall thickness. Magn Reson Imaging. 2005 Jan; 23(1):61-8.Magn Reson Imaging2005-01-01T00:00:002005MR imaging of caveolin gene-specific alterations in right ventricular wall thickness.18936790Quint?s-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu PNature clinical practice. OncologyComplete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol. 2008 Dec; 5(12):737-40.Nat Clin Pract Oncol2008-10-21T00:00:002008Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.Authorship 274722122275506Woodman SE, Lazar AJ, Aldape KD, Davies MAClinical cancer research : an official journal of the American Association for Cancer ResearchNew strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res. 2012 Mar 01; 18(5):1195-200.Clin Cancer Res2012-01-24T00:00:002012New strategies in melanoma: molecular testing in advanced disease.Authorship 28927111Authorship 29071825Authorship 2909912Authorship 2924382Authorship 29325013Authorship 2982988Authorship 29839414Authorship 2996385Authorship 30080319Authorship 3031436Authorship 3040351224743052Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu PMelanoma researchPhase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma. Melanoma Res. 2014 Aug; 24(4):342-8.Melanoma Res2014-08-01T00:00:002014Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma.25148578Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MAThe Journal of investigative dermatologyBeyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.J Invest Dermatol2014-08-22T00:00:002014Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.25185187Peng G, Woodman SE, Mills GBCancer discoveryRADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? Cancer Discov. 2014 Sep; 4(9):988-90.Cancer Discov2014-09-01T00:00:002014RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?25435088Roszik J, Woodman SEBMC genomicsHotSpotter: efficient visualization of driver mutations. BMC Genomics. 2014 Dec 01; 15:1044.BMC Genomics2014-12-01T00:00:002014HotSpotter: efficient visualization of driver mutations.25515650Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SEPigment cell & melanoma researchGenetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res. 2015 May; 28(3):357-9.Pigment Cell Melanoma Res2015-03-23T00:00:002015Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.26058727Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JLHuman pathologyUtility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.Hum Pathol2015-05-06T00:00:002015Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.26206558Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AECancer researchErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res. 2015 Sep 01; 75(17):3554-67.Cancer Res2015-07-23T00:00:002015ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.26216417Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu PCancer immunology researchIntrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunol Res. 2015 Nov; 3(11):1201-6.Cancer Immunol Res2015-07-27T00:00:002015Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.26307133Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KLClinical cancer research : an official journal of the American Association for Cancer ResearchCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.Clin Cancer Res2015-08-25T00:00:002015Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.26439496Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HMJ, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LWT, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang HCancer cellThe Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):515-528.Cancer Cell2015-10-01T00:00:002015The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.26787600Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LNScientific reportsSomatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep. 2016 Jan 20; 6:19649.Sci Rep2016-01-20T00:00:002016Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.74Professor10Assistant Professor14Associate Professor26645196Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Liz?e G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu PCancer discoveryLoss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.Cancer Discov2015-12-08T00:00:002015Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.22936666Yang Y, Liu C, Peng W, Liz?e G, Overwijk WW, Liu Y, Woodman SE, Hwu PBloodAntitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43.Blood2012-08-30T00:00:002012Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.27911979Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MACancerClinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.Cancer2016-12-02T00:00:002016Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.Authorship 841731Authorship 843238Authorship 845925Authorship 847770Authorship 848829Authorship 849349Authorship 850776Authorship 851899Authorship 852954Authorship 856534Authorship 857403Authorship 857761Authorship 859463Authorship 860157Authorship 864835Authorship 866605Authorship 867617Cancer immunology researchIntrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma. Cancer immunology research. 3:1201-1206.Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic MelanomaClinical Cancer ResearchCopy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clinical Cancer Research. 22:374-382.Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanomaCancer CellARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal MelanomaCancer DiscoveryRADical response puts an exceptional responder in CHKmate. Cancer Discovery. 4:988-990.RADical response puts an exceptional responder in CHKmateCancerClinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup> <sup>on-</sup> <sup>V</sup> <sup>600</sup> mutations in cutaneous melanoma patients. Cancer. Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup> <sup>on-</sup> <sup>V</sup> <sup>600</sup> mutations in cutaneous melanoma patientsTargets by organ site. Targets by organ siteClinical Cancer ResearchInflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clinical Cancer Research. 22:3016-3024.Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanomaTargets by organ site. Targets by organ sitePigment Cell and Melanoma ResearchGenetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell and Melanoma Research. 28:357-359.Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell lineCancer DiscoveryAnalysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockadeCancerUveal melanoma. Cancer. Uveal melanomaOncoImmunologyDistinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. 5.Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaBMC MedicineNovel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. 14.Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setCellLoss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 167:397-404.e9.Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyClinical Cancer ResearchIntegrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clinical Cancer Research. 15:7538-7546.Integrated molecular and clinical analysis of AKT activation in metastatic melanomaScientific ReportsSomatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports. 6.Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene ExpressionCancer CellThe Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 28:515-528.The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers29496759Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Liz?e G, Woodman SE, Hwu PClinical cancer research : an official journal of the American Association for Cancer ResearchThe RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.Clin Cancer Res2018-03-01T00:00:002018The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.29628419Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng WCell metabolismIncreased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018 May 01; 27(5):977-987.e4.Cell Metab2018-04-05T00:00:002018Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.Authorship 88814913Authorship 88833623Authorship 88867435Authorship 89003431D022461Chemicals & Drugs20740.957766CaveolinsD048493Chemicals & Drugs32012770.583873Proto-Oncogene Proteins B-rafD014604Disorders591750.842403Uveal NeoplasmsAuthorship 9002197Authorship 90463810Authorship 90602010Authorship 9068147Authorship 90707315Authorship 90996927Authorship 91081810Authorship 91251116Authorship 91278528Authorship 91591442Authorship 91851031Authorship 9202917Authorship 92217431Authorship 92277339Authorship 92308422Authorship 9250888Authorship 92666113Authorship 9270462Authorship 93006736Authorship 93010719Authorship 93069419Authorship 93518831Authorship 93735919Authorship 93994819Authorship 9399812019996208Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JEClinical cancer research : an official journal of the American Association for Cancer ResearchIntegrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009 Dec 15; 15(24):7538-7546.Clin Cancer Res2009-12-15T00:00:002009Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.26783288Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EAClinical cancer research : an official journal of the American Association for Cancer ResearchInflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.Clin Cancer Res2016-01-18T00:00:002016Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.27089234Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko JM, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SEPigment cell & melanoma researchComparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res. 2016 07; 29(4):470-3.Pigment Cell Melanoma Res2016-07-01T00:00:002016Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum.27301722Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JACancer discoveryAnalysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.Cancer Discov2016-06-14T00:00:002016Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.27141370Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JAOncoimmunologyDistinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044.Oncoimmunology2016-02-02T00:00:002016Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.27265506Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, Woodman SE, Harbour JW, Thomas KR, Odelberg SJ, Ostanin K, Li DYCancer cellARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell. 2016 06 13; 29(6):889-904.Cancer Cell2016-06-02T00:00:002016ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.26991400Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SPCancerUveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016 08 01; 122(15):2299-312.Cancer2016-03-15T00:00:002016Uveal melanoma: From diagnosis to treatment and the science in between.27667683Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma PCellLoss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.Cell2016-09-22T00:00:002016Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.27776519Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SEBMC medicineNovel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.BMC Med2016-10-25T00:00:002016Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.28594900Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, 't Hoen PAC, Garraway LA, Woodman SEPloS oneSystematic genomic and translational efficiency studies of uveal melanoma. PLoS One. 2017; 12(6):e0178189.PLoS One2017-06-08T00:00:002017Systematic genomic and translational efficiency studies of uveal melanoma.28251903Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PAScience translational medicineIntegrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).Sci Transl Med2017-03-01T00:00:002017Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.28399339Jager MJ, Dogrus?z M, Woodman SEAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr; 6(2):179-185.Asia Pac J Ophthalmol (Phila)2017-03-01T00:00:002017Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases.D044385Chemicals & Drugs27340.969616GTP-Binding Protein alpha Subunits28630054Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Liz?e G, Yee CCancer immunology researchSLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunol Res. 2017 08; 5(8):618-629.Cancer Immunol Res2017-06-19T00:00:002017SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.28810145Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SECancer cellIntegrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017 08 14; 32(2):204-220.e15.Cancer Cell2017-08-14T00:00:002017Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.28819565Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JANPJ genomic medicineGenomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.NPJ Genom Med2017-04-07T00:00:002017Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.29316429Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SECancer cellIntegrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2018 01 08; 33(1):151.Cancer Cell2018-01-08T00:00:002018Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.29387478Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MAESMO openRetrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283.ESMO Open2018-01-24T00:00:002018Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.29848573Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez CClinical cancer research : an official journal of the American Association for Cancer ResearchProspective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.Clin Cancer Res2018-05-30T00:00:002018Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.29361468Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JAThe Lancet. OncologyNeoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.Lancet Oncol2018-01-18T00:00:002018Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.30012853Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DLCancer discoveryCD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175.Cancer Discov2018-07-16T00:00:002018CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.30094412Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SEJCO precision oncologyTargeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol. 2018; 2018.JCO Precis Oncol2018-06-05T00:00:002018Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.30297909Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicineNeoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.Nat Med2018-10-08T00:00:002018Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.30305177Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab AJournal for immunotherapy of cancerInfliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018 10 11; 6(1):103.J Immunother Cancer2018-10-11T00:00:002018Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.30361510Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicineAuthor Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.Nat Med2018-12-01T00:00:002018Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.30361511Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicinePublisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.Nat Med2018-12-01T00:00:002018Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.D008545Disorders68053010.290068MelanomaPathologyAuthorship 9427741630798855McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, Lazar AJ, Woodman SEThe Journal of investigative dermatologyTyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol. 2019 03; 139(3):728-731.J Invest Dermatol2018-10-25T00:00:002018Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.Authorship 9452172030995944Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab AJournal for immunotherapy of cancerCorrection to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2019 Apr 17; 7(1):107.J Immunother Cancer2019-04-17T00:00:002019Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.Authorship 955942631550176Zeng J, Johnson A, Shufean MA, Kahle M, Yang D, Woodman SE, Vu T, Moorthy S, Holla V, Meric-Bernstam FJCO clinical cancer informaticsOperationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. JCO Clin Cancer Inform. 2019 09; 3:1-12.JCO Clin Cancer Inform2019-09-01T00:00:002019Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.Authorship 9569311231596927Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SEInvestigative ophthalmology & visual scienceElevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Invest Ophthalmol Vis Sci. 2019 10 01; 60(13):4187-4195.Invest Ophthalmol Vis Sci2019-10-01T00:00:002019Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma.Authorship 9758662731942075Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Saut?s-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JANatureB cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.Nature2020-01-15T00:00:002020B cells and tertiary lymphoid structures promote immunotherapy response.Authorship 1000110832976223Mattei J, Ballhausen A, Bassett R, Shephard M, Chattopadhyay C, Hudgens C, Tetzlaff M, Woodman S, Sato T, Patel SPMelanoma researchA phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. Melanoma Res. 2020 12; 30(6):574-579.Melanoma Res2020-12-01T00:00:002020A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma.Authorship 1018895234008215Oba J, Woodman SEThe Journal of dermatologyThe genetic and epigenetic basis of distinct melanoma types. J Dermatol. 2021 Jul; 48(7):925-939.J Dermatol2021-05-18T00:00:002021The genetic and epigenetic basis of distinct melanoma types.Authorship 10235285134239137Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JANature medicineGut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.Nat Med2021-07-08T00:00:002021Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.Authorship 10250973134261675Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DMCancer discoveryEfficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.Cancer Discov2021-07-14T00:00:002021Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.Authorship 10258102434289358Terranova CJ, Tang M, Maitituoheti M, Raman AT, Ghosh AK, Schulz J, Amin SB, Orouji E, Tomczak K, Sarkar S, Oba J, Creasy C, Wu CJ, Khan S, Lazcano R, Wani K, Singh A, Barrodia P, Zhao D, Chen K, Haydu LE, Wang WL, Lazar AJ, Woodman SE, Bernatchez C, Rai KCell reportsReprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Rep. 2021 07 20; 36(3):109410.Cell Rep2021-07-20T00:00:002021Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.Authorship 103403920Authorship 10341302734771465Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JACancersIdentification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21).Cancers (Basel)2021-10-22T00:00:002021Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.34777916White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JAOncoimmunologyShort-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.Oncoimmunology2021-11-06T00:00:002021Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma.Authorship 10359096234941392Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JAScience (New York, N.Y.)Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.Science2021-12-23T00:00:002021Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Authorship 104348625Authorship 1044485435389428Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JCJAMA oncologyAssessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 06 01; 8(6):904-909.JAMA Oncol2022-06-01T00:00:002022Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.35470980Madani M, Goldstein D, Stefanescu R, Woodman SE, Rojas-Hernandez CMCancer medicineCharacterization of coagulopathy and outcomes in cancer patients with severe COVID -19 illness: Longitudinal changes in hospitalized cancer patients. Cancer Med. 2022 10; 11(20):3771-3785.Cancer Med2022-04-26T00:00:002022Characterization of coagulopathy and outcomes in cancer patients with severe COVID -19 illness: Longitudinal changes in hospitalized cancer patients.Authorship 10480562335705814Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JANatureAndrogen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.Nature2022-06-15T00:00:002022Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.Authorship 10504823535810190Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SENature communicationsMulti-modal molecular programs regulate melanoma cell state. Nat Commun. 2022 07 09; 13(1):4000.Nat Commun2022-07-09T00:00:002022Multi-modal molecular programs regulate melanoma cell state.Authorship 105920220Authorship 105938025Authorship 10578882436612278Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver N, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, Wu CC, Chung C, Wu JCancersHabitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel). 2022 Dec 31; 15(1).Cancers (Basel)2022-12-31T00:00:002022Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19.36166093Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JLClinical cancer research : an official journal of the American Association for Cancer ResearchObesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.Clin Cancer Res2023-01-04T00:00:002023Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.36627494Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JANatureAuthor Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.Nature2023-01-01T00:00:002023Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.Authorship 1064556536836508Cata JP, Hu J, Feng L, Chung C, Woodman SE, Meyer LAJournal of personalized medicineAssociation between COVID-19 and Postoperative Neurological Complications and Antipsychotic Medication Use after Cancer Surgery: A Retrospective Study. J Pers Med. 2023 Jan 31; 13(2).J Pers Med2023-01-31T00:00:002023Association between COVID-19 and Postoperative Neurological Complications and Antipsychotic Medication Use after Cancer Surgery: A Retrospective Study.Authorship 10647461336868753Reddy DR, Cuenca JA, Botdorf J, Muthu M, Hanmandlu A, Wegner R, Crommett J, Gutierrez C, Rathi N, Sajith B, Knafl M, Abbas HA, Woodman SE, Nates JL, D3CODE Team CollaboratorsMayo Clinic proceedingsClinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clin Proc. 2023 03; 98(3):451-457.Mayo Clin Proc2022-12-28T00:00:002022Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19.Authorship 10905781538473297Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang JCancersClinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers (Basel). 2024 Feb 26; 16(5).Cancers (Basel)2024-02-26T00:00:002024Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor